Company intelligence / Profile preview

Blaze Ahead

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

Lead program BLZ-100 (tozuleristide, Tumor Paint) has completed enrollment in a pivotal Phase 2/3 trial for pediatric central nervous system tumors, showing progress towards registration. Prior Phase 1 studies demonstrated proof of concept in brain, breast, and skin cancers[5].

Therapeutic areas: Oncology
Modalities: PeptidesDiagnostic device
Industry: Biotech

Partnerships

Fred Hutchinson Cancer Center (Optide discovery agreements)Seattle Children’s Hospital (pivotal trial network)Pacific Pediatric Neuro-Oncology Consortium (trial coordination)Ideagen (quality management software)

Beyond the preview

Go deeper on Blaze Ahead.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blaze Ahead.

Explore the full profile